Kazia Therapeutics Limited
ASX:KZA.AX
Overview | Financials
Company Name | Kazia Therapeutics Limited |
Symbol | KZA.AX |
Currency | AUD |
Price | 0.08 |
Market Cap | 18,907,919 |
Dividend Yield | 0% |
52-week-range | 0.051 - 0.24 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. John E. Friend II, M.D. |
Website | https://www.kaziatherapeutics.com |
An error occurred while fetching data.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD